Tymlos (Abaloparatide) Patent Expiration, LOE Window & CMS Spending

Tymlos (Abaloparatide) by Radius Health: FDA Orange Book LOE 2040-01-10, 0 AB generics, $272.4M 2024 CMS Part D & Medicaid spend, and 8 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRadius Health
FDA Application & PathwayN208743 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2040-01-10
Orange Book Patents (*PED Extensions)9 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$272.4M
2024 Medicare Part D Spend$257.6M
2024 Medicaid Spend$14.8M
Reported Wholesale Price Change (CA SB 17)8 WAC filings (max 27.9% 2-yr change)